159 related articles for article (PubMed ID: 29667005)
1. The BMP-2 mutant L51P: a BMP receptor IA binding-deficient inhibitor of noggin.
Khattab HM; Kubota S; Takigawa M; Kuboki T; Sebald W
J Bone Miner Metab; 2019 Mar; 37(2):199-205. PubMed ID: 29667005
[TBL] [Abstract][Full Text] [Related]
2. L51P - A BMP2 variant with osteoinductive activity via inhibition of Noggin.
Albers CE; Hofstetter W; Sebald HJ; Sebald W; Siebenrock KA; Klenke FM
Bone; 2012 Sep; 51(3):401-6. PubMed ID: 22750402
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of endogenous antagonists with an engineered BMP-2 variant increases BMP-2 efficacy in rat femoral defect healing.
Sebald HJ; Klenke FM; Siegrist M; Albers CE; Sebald W; Hofstetter W
Acta Biomater; 2012 Oct; 8(10):3816-20. PubMed ID: 22750247
[TBL] [Abstract][Full Text] [Related]
4. The BMP2 antagonist inhibitor L51P enhances the osteogenic potential of BMP2 by simultaneous and delayed synergism.
Khattab HM; Ono M; Sonoyama W; Oida Y; Shinkawa S; Yoshioka Y; Maekawa K; Tabata Y; Sugama K; Sebald W; Kuboki T
Bone; 2014 Dec; 69():165-73. PubMed ID: 25240457
[TBL] [Abstract][Full Text] [Related]
5. Molecular recognition of BMP-2 and BMP receptor IA.
Keller S; Nickel J; Zhang JL; Sebald W; Mueller TD
Nat Struct Mol Biol; 2004 May; 11(5):481-8. PubMed ID: 15064755
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening and selection of drug-like compounds to block noggin interaction with bone morphogenetic proteins.
Ahmed S; Metpally RP; Sangadala S; Reddy BV
J Mol Graph Model; 2010 Apr; 28(7):670-82. PubMed ID: 20137990
[TBL] [Abstract][Full Text] [Related]
7. The BMP2 variant L51P restores the osteogenic differentiation of human mesenchymal stromal cells in the presence of intervertebral disc cells.
Tekari A; May RD; Frauchiger DA; Chan SC; Benneker LM; Gantenbein B
Eur Cell Mater; 2017 Feb; 33():197-210. PubMed ID: 28266688
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
9. Structure of Gremlin-1 and analysis of its interaction with BMP-2.
Kišonaitė M; Wang X; Hyvönen M
Biochem J; 2016 Jun; 473(11):1593-604. PubMed ID: 27036124
[TBL] [Abstract][Full Text] [Related]
10. Surface-mediated delivery of siRNA from fibrin hydrogels for knockdown of the BMP-2 binding antagonist noggin.
Kowalczewski CJ; Saul JM
Acta Biomater; 2015 Oct; 25():109-20. PubMed ID: 26234488
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of BMPs and BMP-inhibitors in human fractures and non-unions.
Kloen P; Lauzier D; Hamdy RC
Bone; 2012 Jul; 51(1):59-68. PubMed ID: 22521262
[TBL] [Abstract][Full Text] [Related]
12. Granulosal and thecal expression of bone morphogenetic protein- and activin-binding protein mRNA transcripts during bovine follicle development and factors modulating their expression in vitro.
Glister C; Satchell L; Knight PG
Reproduction; 2011 Oct; 142(4):581-91. PubMed ID: 21821720
[TBL] [Abstract][Full Text] [Related]
13. A BMP/activin A chimera is superior to native BMPs and induces bone repair in nonhuman primates when delivered in a composite matrix.
Seeherman HJ; Berasi SP; Brown CT; Martinez RX; Juo ZS; Jelinsky S; Cain MJ; Grode J; Tumelty KE; Bohner M; Grinberg O; Orr N; Shoseyov O; Eyckmans J; Chen C; Morales PR; Wilson CG; Vanderploeg EJ; Wozney JM
Sci Transl Med; 2019 Apr; 11(489):. PubMed ID: 31019025
[TBL] [Abstract][Full Text] [Related]
14. Biphasic effects of transforming growth factor β on bone morphogenetic protein-induced osteoblast differentiation.
de Gorter DJ; van Dinther M; Korchynskyi O; ten Dijke P
J Bone Miner Res; 2011 Jun; 26(6):1178-87. PubMed ID: 21611961
[TBL] [Abstract][Full Text] [Related]
15. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN.
Reddi AH
Arthritis Res; 2001; 3(1):1-5. PubMed ID: 11178121
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of BMP-2 and BMP-7 interactions with antagonists Gremlin-1 and Noggin in Glioblastoma tumors.
Choudhuri KSR; Mishra S
J Comput Chem; 2020 Nov; 41(30):2544-2561. PubMed ID: 32935366
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates do not affect healing of a critical-size defect in estrogen-deficient mice.
Strunz F; Gentil-Perret S; Siegrist M; Bohner M; Saulacic N; Hofstetter W
Bone Rep; 2024 Mar; 20():101739. PubMed ID: 38304619
[TBL] [Abstract][Full Text] [Related]
18. The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists.
Nickel J; Dreyer MK; Kirsch T; Sebald W
J Bone Joint Surg Am; 2001; 83-A Suppl 1(Pt 1):S7-14. PubMed ID: 11263668
[TBL] [Abstract][Full Text] [Related]
19. Bone Morphogenetic Proteins: Promising Molecules for Bone Healing, Bioengineering, and Regenerative Medicine.
Carreira AC; Zambuzzi WF; Rossi MC; Astorino Filho R; Sogayar MC; Granjeiro JM
Vitam Horm; 2015; 99():293-322. PubMed ID: 26279381
[TBL] [Abstract][Full Text] [Related]
20. Deletion mutants of BMP folding variants act as BMP antagonists and are efficient inhibitors for heterotopic ossification.
Weber FE; Schmökel H; Oelgeschläger M; Nickel J; Maly FE; Hortschansky P; Grätz KW
J Bone Miner Res; 2003 Dec; 18(12):2142-51. PubMed ID: 14672349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
